Stocks
Dicerna Pharmaceuticals Financial Statements (DRNA) |
||||||||||
| Dicerna Pharmaceuticalssmart-lab.ru | % | 2016 | 2017 | 2018 | 2019 | 2020 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 30.03.2017 | 08.03.2018 | 13.03.2019 | 28.02.2020 | 26.02.2021 | 09.11.2021 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.295 | 2.28 | 6.18 | 23.9 | 164.3 | 192.9 | |||
| Operating Income, bln rub | -59.7 | -60.6 | -61.2 | -128.2 | -113.2 | -121.3 | ||||
| EBITDA, bln rub | ? | -58.7 | -59.3 | -87.5 | -119.2 | -110.5 | -118.5 | |||
| Net profit, bln rub | ? | -59.5 | -60.0 | -88.9 | -120.5 | -112.7 | -124.4 | |||
| OCF, bln rub | ? | -48.7 | -45.3 | 18.3 | -0.692 | 175.1 | 21.1 | |||
| CAPEX, bln rub | ? | 0.449 | 0.133 | 0.359 | 6.35 | 11.7 | 12.5 | |||
| FCF, bln rub | ? | -49.2 | -45.5 | 17.9 | -7.04 | 163.4 | 8.56 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 60.0 | 62.9 | 67.4 | 152.1 | 277.5 | 314.1 | ||||
| Cost of production, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| R&D, bln rub | 41.7 | 37.0 | 45.7 | 109.3 | 205.4 | 227.4 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.603 | 0.003 | 0.020 | 0.012 | ||||
| Assets, bln rub | 51.3 | 120.9 | 409.0 | 597.4 | 707.8 | 772.1 | ||||
| Net Assets, bln rub | ? | 41.2 | 101.2 | 200.7 | 152.2 | 137.8 | 107.7 | |||
| Debt, bln rub | 0.000 | 0.000 | 0.000 | 23.5 | 52.2 | 64.4 | ||||
| Cash, bln rub | 45.9 | 113.7 | 302.6 | 348.9 | 568.8 | 565.5 | ||||
| Net debt, bln rub | -45.9 | -113.7 | -302.6 | -325.4 | -516.7 | -501.1 | ||||
| Ordinary share price, rub | 2.88 | 9.03 | 10.7 | 22.0 | 22.0 | 38.0 | ||||
| Number of ordinary shares, mln | 20.7 | 20.7 | 55.6 | 68.4 | 74.5 | 77.7 | ||||
| Market cap, bln rub | 60 | 187 | 595 | 1 507 | 1 642 | 2 951 | ||||
| EV, bln rub | ? | 14 | 73 | 292 | 1 182 | 1 125 | 2 450 | |||
| Book value, bln rub | 41 | 101 | 201 | 152 | 138 | 108 | ||||
| EPS, rub | ? | -2.87 | -2.90 | -1.60 | -1.76 | -1.51 | -1.60 | |||
| FCF/share, rub | -2.37 | -2.19 | 0.32 | -0.10 | 2.19 | 0.11 | ||||
| BV/share, rub | 1.99 | 4.89 | 3.61 | 2.22 | 1.85 | 1.38 | ||||
| EBITDA margin, % | ? | -19 889% | -2 603% | -1 416% | -498.7% | -67.3% | -61.5% | |||
| Net margin, % | ? | -20 174% | -2 637% | -1 439% | -503.9% | -68.6% | -64.5% | |||
| FCF yield, % | ? | -82.4% | -24.3% | 3.02% | -0.47% | 9.95% | 0.29% | |||
| ROE, % | ? | -144.4% | -59.3% | -44.3% | -79.1% | -81.8% | -115.6% | |||
| ROA, % | ? | -116.1% | -49.7% | -21.7% | -20.2% | -15.9% | -16.1% | |||
| P/E | ? | -1.00 | -3.12 | -6.69 | -12.5 | -14.6 | -23.7 | |||
| P/FCF | -1.21 | -4.12 | 33.1 | -214.1 | 10.0 | 344.9 | ||||
| P/S | ? | 202.3 | 82.2 | 96.3 | 63.1 | 9.99 | 15.3 | |||
| P/BV | ? | 1.45 | 1.85 | 2.96 | 9.90 | 11.9 | 27.4 | |||
| EV/EBITDA | ? | -0.24 | -1.24 | -3.34 | -9.92 | -10.2 | -20.7 | |||
| Debt/EBITDA | 0.78 | 1.92 | 3.46 | 2.73 | 4.68 | 4.23 | ||||
| R&D/CAPEX, % | 9 286% | 27 807% | 12 733% | 1 722% | 1 748% | 1 820% | ||||
| CAPEX/Revenue, % | 152.2% | 5.84% | 5.81% | 26.6% | 7.15% | 6.48% | ||||
| Dicerna Pharmaceuticals shareholders | ||||||||||
